国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
多烯磷脂酰胆碱联合干扰素α治疗慢性乙型肝炎
Clinical Observation of the Treatment of HBeAg Negative Chronic Hepatitis B with PPC and Interferon Alpha
投稿时间:2006-11-14  修订日期:2006-12-27
DOI:
中文关键词:  多烯磷脂酰胆碱  干扰素α  肝炎  乙型  慢性
英文关键词:PPC  Interferon alpha  Chronic hepatitis B
基金项目:
沈雁冰  谢迎春
三峡大学第一临床医学院宜昌市中心人民医院,湖北宜昌443003
摘要点击次数: 2595
全文下载次数: 104
中文摘要:
      目的:探讨多烯磷脂酰胆碱(PPC,易善复)联合干扰素α治疗HBeAg阴性慢性乙型肝炎的疗效。方法:将80例患者随机分成治疗组60例和对照组20例,前者采用PPC联合干扰素α治疗24周,后者同期仅采用干扰素仅治疗,对照观察两组疗程结束时免疫应答及随访24周时持续应答情况。结果:治疗组和对照组疗程结束时免疫应答数分别为46(76.67%),8(40.00%),χ^2=9.193,P〈0.01;两组随访24周末持续应答数分别为40(66.67%),6(30.00%),χ^2=8.252,P〈0.01,两组具有显著性差异。结论:采用PPC联合干扰素α治疗HBeAg阴性慢性乙型肝炎近期疗效优于单用干扰素α,值得临床推广应用。
英文摘要:
      Objective:To discuss the curative effect of the treatment of the HBeAg by using PPC combined with interferon a. Method: 80 patients were randomly divided into a group of 60 patients and a group of 20 patients. The former group was administered with PPC together with interferon a for 24 weeks. Meanwhile, the latter were administered only with interferon a. When the treatment ended, the immunity response of the two groups continued to be observed and visited for 24 weeks. Result: The parameters for immunity response were 46(76.67%) and 8(40.00%) respectively,x2=9.193,P<0.01;the parameters for continuous response were 40(66.67%)and 6(30.00%) respectively,x2=8.252, P<0.01. There were distinct differences in the results. Conclusion:The recent curative effect of the treatment of the HBeAg by using PPC combined with interferon a is better than that by using interferon a separately and the method deserves spreading.
查看全文  查看/发表评论  下载PDF阅读器
关闭